Pegfilgrastim
Pegfilgrastim is an active ingredient of the class «immunostimulant».
Pharmaceutical drug
What it is used for
- B-cell lymphoma
- Agranulocytosis
- Diffuse large B-cell lymphoma
- Lymphoma
- Lung carcinoma in situ
- Colon cancer
- Neutropenia
- Non-Hodgkin lymphoma
- Chronic lymphocytic leukemia
- Neoplasm
- Infection
Armlupeg is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
How it works
- Granulocyte colony stimulating factor receptor agonist
Class: immunostimulant
Common side effects
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Splenic Rupture Acute Respiratory Distress Syndrome Serious Hypersensitivity Reactions Use in Patients with Sickle Cell Disorders Glomerulonephritis Leukocytosis Thrombocytopenia Capillary Leak…
Who should not take it
Armlupeg is contraindicated in patients with a history of a serious hypersensitivity reaction to pegfilgrastim products or filgrastim products.
Pregnancy and breastfeeding
Although available data with pegfilgrastim product use in pregnant women are insufficient to establish whether there is a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, there are available data from published…
Brand names
European Union
Cavoley · Dyrupeg · Grasustek · Nylaspeg · Pelgraz · Vivlipeg
Canada
Armlupeg · Dyrupeg · Lapelga · Niopeg · Pexegra
Other trade names
Neulasta sureclick · Ristempa
Approval status
- US Food and Drug Administration
- prescription · since 2002
- European Medicines Agency
- authorised · since 2002
- Health Canada
- prescription · marketed
- First approval anywhere
- 2002
Codes
- ATC
- L03AA13
- RxNorm CUI
- 338036
- ChEMBL
- CHEMBL1201568
- UNII
- 3A58010674
- Wikidata
- Q1592932
Frequently asked questions
What is Pegfilgrastim used for?
Pegfilgrastim is used for: B-cell lymphoma, Agranulocytosis, Diffuse large B-cell lymphoma, Lymphoma, Lung carcinoma in situ, Colon cancer, Neutropenia, and Non-Hodgkin lymphoma.
What kind of medicine is Pegfilgrastim?
Pegfilgrastim is an active ingredient of the class «immunostimulant».
What are the brand names of Pegfilgrastim?
Brand names of Pegfilgrastim include Cavoley, Dyrupeg, Grasustek, Nylaspeg, Pelgraz, Vivlipeg, Armlupeg, and Lapelga.
Medicines in the same class
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)